271 related articles for article (PubMed ID: 35092743)
1. Probability of HBsAg loss after nucleo(s)tide analogue withdrawal depends on HBV genotype and viral antigen levels.
Sonneveld MJ; Chiu SM; Park JY; Brakenhoff SM; Kaewdech A; Seto WK; Tanaka Y; Carey I; Papatheodoridi M; van Bömmel F; Berg T; Zoulim F; Ahn SH; Dalekos GN; Erler NS; Höner Zu Siederdissen C; Wedemeyer H; Cornberg M; Yuen MF; Agarwal K; Boonstra A; Buti M; Piratvisuth T; Papatheodoridis G; Chen CH; Maasoumy B;
J Hepatol; 2022 May; 76(5):1042-1050. PubMed ID: 35092743
[TBL] [Abstract][Full Text] [Related]
2. Prediction of Sustained Response After Nucleo(s)tide Analogue Cessation Using HBsAg and HBcrAg Levels: A Multicenter Study (CREATE).
Sonneveld MJ; Park JY; Kaewdech A; Seto WK; Tanaka Y; Carey I; Papatheodoridi M; van Bömmel F; Berg T; Zoulim F; Ahn SH; Dalekos GN; Erler NS; Höner Zu Siederdissen C; Wedemeyer H; Cornberg M; Yuen MF; Agarwal K; Boonstra A; Buti M; Piratvisuth T; Papatheodoridis G; Maasoumy B;
Clin Gastroenterol Hepatol; 2022 Apr; 20(4):e784-e793. PubMed ID: 33309804
[TBL] [Abstract][Full Text] [Related]
3. Relationship between hepatitis B core-related antigen levels and sustained HBeAg seroconversion in patients treated with nucleo(s)tide analogues.
Sonneveld MJ; van Oord GW; van Campenhout MJ; De Man RA; Janssen HLA; de Knegt RJ; Boonstra A; van der Eijk AA
J Viral Hepat; 2019 Jul; 26(7):828-834. PubMed ID: 30896057
[TBL] [Abstract][Full Text] [Related]
4. Lower pretreatment HBV DNA levels are associated with better off-treatment outcomes after nucleo(s)tide analogue withdrawal in patients with HBeAg-negative chronic hepatitis B: A multicentre cohort study.
Sonneveld MJ; Chiu SM; Park JY; Brakenhoff SM; Kaewdech A; Seto WK; Tanaka Y; Carey I; Papatheodoridi M; Colombatto P; van Bömmel F; Berg T; Zoulim F; Ahn SH; Dalekos GN; Erler NS; Brunetto M; Wedemeyer H; Cornberg M; Yuen MF; Agarwal K; Boonstra A; Buti M; Piratvisuth T; Papatheodoridis G; Chen CH; Maasoumy B;
JHEP Rep; 2023 Aug; 5(8):100790. PubMed ID: 37484211
[TBL] [Abstract][Full Text] [Related]
5. HBV DNA and HBsAg Levels at 24 Weeks Off-Treatment Predict Clinical Relapse and HBsAg Loss in HBeAg-Negative Patients Who Discontinued Antiviral Therapy.
Sonneveld MJ; Chiu SM; Park JY; Brakenhoff SM; Kaewdech A; Seto WK; Tanaka Y; Carey I; Papatheodoridi M; Colombatto P; van Bömmel F; Janssen HL; Berg T; Zoulim F; Ahn SH; Dalekos GN; Erler NS; Brunetto M; Wedemeyer H; Cornberg M; Yuen MF; Agarwal K; Boonstra A; Buti M; Piratvisuth T; Papatheodoridis G; Chen CH; Maasoumy B;
Gastroenterology; 2024 Jan; 166(1):168-177.e8. PubMed ID: 37769952
[TBL] [Abstract][Full Text] [Related]
6. Hepatitis B virus RNA decline without concomitant viral antigen decrease is associated with a low probability of sustained response and hepatitis B surface antigen loss.
Brakenhoff SM; de Man RA; Boonstra A; van Campenhout MJH; de Knegt RJ; van Bömmel F; van der Eijk AA; Berg T; Hansen BE; Janssen HLA; Sonneveld MJ
Aliment Pharmacol Ther; 2021 Jan; 53(2):314-320. PubMed ID: 33222190
[TBL] [Abstract][Full Text] [Related]
7. Durable hepatitis B surface antigen decline in hepatitis B e antigen-positive chronic hepatitis B patients treated with pegylated interferon-α2b: relation to response and HBV genotype.
Sonneveld MJ; Rijckborst V; Cakaloglu Y; Simon K; Heathcote EJ; Tabak F; Mach T; Boucher CA; Hansen BE; Zeuzem S; Janssen HL
Antivir Ther; 2012; 17(1):9-17. PubMed ID: 22267464
[TBL] [Abstract][Full Text] [Related]
8. Pregenomic HBV RNA and Hepatitis B Core-Related Antigen Predict Outcomes in Hepatitis B e Antigen-Negative Chronic Hepatitis B Patients Suppressed on Nucleos(T)ide Analogue Therapy.
Carey I; Gersch J; Wang B; Moigboi C; Kuhns M; Cloherty G; Dusheiko G; Agarwal K
Hepatology; 2020 Jul; 72(1):42-57. PubMed ID: 31701544
[TBL] [Abstract][Full Text] [Related]
9. Significance of serum HBV RNA in non-cirrhotic HBeAg-negative chronic hepatitis B patients who discontinue effective antiviral therapy.
Papatheodoridi M; Papachristou E; Moschidis Z; Hadziyannis E; Rigopoulou E; Zachou K; Villeret F; Magiorkinis G; Lyberopoulou A; Gatselis N; Vlachogiannakos I; Manolakopoulos S; Dalekos GN; Zoulim F; Paraskevis D; Papatheodoridis GV
J Viral Hepat; 2022 Nov; 29(11):948-957. PubMed ID: 35789515
[TBL] [Abstract][Full Text] [Related]
10. A multicenter randomized-controlled trial of nucleos(t)ide analogue cessation in HBeAg-negative chronic hepatitis B.
van Bömmel F; Stein K; Heyne R; Petersen J; Buggisch P; Berg C; Zeuzem S; Stallmach A; Sprinzl M; Schott E; Pathil-Warth A; von Arnim U; Keitel V; Lohmeyer J; Simon KG; Trautwein C; Trein A; Hüppe D; Cornberg M; Lammert F; Ingiliz P; Zachoval R; Hinrichsen H; Zipprich A; Klinker H; Schulze Zur Wiesch J; Schmiedeknecht A; Brosteanu O; Berg T
J Hepatol; 2023 May; 78(5):926-936. PubMed ID: 37062574
[TBL] [Abstract][Full Text] [Related]
11. Viral and immune factors associated with successful treatment withdrawal in HBeAg-negative chronic hepatitis B patients.
García-López M; Lens S; Pallett LJ; Testoni B; Rodríguez-Tajes S; Mariño Z; Bartres C; García-Pras E; Leonel T; Perpiñán E; Lozano JJ; Rodríguez-Frías F; Koutsoudakis G; Zoulim F; Maini MK; Forns X; Pérez-Del-Pulgar S
J Hepatol; 2021 May; 74(5):1064-1074. PubMed ID: 33278456
[TBL] [Abstract][Full Text] [Related]
12. A critique and systematic review of the clinical utility of hepatitis B core-related antigen.
Adraneda C; Tan YC; Yeo EJ; Kew GS; Khakpoor A; Lim SG
J Hepatol; 2023 Apr; 78(4):731-741. PubMed ID: 36586590
[TBL] [Abstract][Full Text] [Related]
13. Clinical utility of quantitative HBsAg in natural history and nucleos(t)ide analogue treatment of chronic hepatitis B: new trick of old dog.
Tseng TC; Kao JH
J Gastroenterol; 2013 Jan; 48(1):13-21. PubMed ID: 23090000
[TBL] [Abstract][Full Text] [Related]
14. Monitoring of serum HBV RNA, HBcrAg, HBsAg and anti-HBc levels in patients during long-term nucleoside/nucleotide analogue therapy.
Liao H; Liu Y; Li X; Wang J; Chen X; Zou J; Li Q; Liu L; Wang J; Huang B; Lu F; Xu D
Antivir Ther; 2019; 24(2):105-115. PubMed ID: 30511941
[TBL] [Abstract][Full Text] [Related]
15. Low Hepatitis B Core-Related Antigen Levels Correlate Higher Spontaneous Seroclearance of Hepatitis B Surface Antigen in Chronic Hepatitis B Patients With High Hepatitis B Surface Antigen Levels.
Tseng TC; Chiang C; Liu CJ; Hong CM; Su TH; Yang HC; Yang WT; Liu CH; Chen PJ; Kao JH
Gastroenterology; 2023 Apr; 164(4):669-679.e6. PubMed ID: 36642151
[TBL] [Abstract][Full Text] [Related]
16. Rebound of HBV DNA after cessation of nucleos/tide analogues in chronic hepatitis B patients with undetectable covalently closed.
Lai CL; Wong DK; Wong GT; Seto WK; Fung J; Yuen MF
JHEP Rep; 2020 Jun; 2(3):100112. PubMed ID: 32462119
[TBL] [Abstract][Full Text] [Related]
17. End-of-treatment HBsAg, HBcrAg and HBV RNA predict the risk of off-treatment ALT flares in chronic hepatitis B patients.
Brakenhoff SM; de Knegt RJ; van Campenhout MJH; van der Eijk AA; Brouwer WP; van Bömmel F; Boonstra A; Hansen BE; Berg T; Janssen HLA; de Man RA; Sonneveld MJ
J Microbiol Immunol Infect; 2023 Feb; 56(1):31-39. PubMed ID: 35941076
[TBL] [Abstract][Full Text] [Related]
18. Combining end-of-treatment HBsAg and baseline hepatitis B core-related antigen reduce HBV relapse rate after tenofovir cessation.
Kuo YH; Wang JH; Hung CH; Lu SN; Hu TH; Chen CH
Hepatol Int; 2021 Apr; 15(2):301-309. PubMed ID: 33665773
[TBL] [Abstract][Full Text] [Related]
19. Combining Hepatitis B Virus RNA and Hepatitis B Core-Related Antigen: Guidance for Safely Stopping Nucleos(t)ide Analogues in Hepatitis B e Antigen-Positive Patients With Chronic Hepatitis B.
Fan R; Peng J; Xie Q; Tan D; Xu M; Niu J; Wang H; Ren H; Chen X; Wang M; Sheng J; Tang H; Bai X; Wu Y; Zhou B; Sun J; Hou J;
J Infect Dis; 2020 Jul; 222(4):611-618. PubMed ID: 32211776
[TBL] [Abstract][Full Text] [Related]
20. Serum hepatitis B core-related antigen is more accurate than hepatitis B surface antigen to identify inactive carriers, regardless of hepatitis B virus genotype.
Riveiro-Barciela M; Bes M; Rodríguez-Frías F; Tabernero D; Ruiz A; Casillas R; Vidal-González J; Homs M; Nieto L; Sauleda S; Esteban R; Buti M
Clin Microbiol Infect; 2017 Nov; 23(11):860-867. PubMed ID: 28288829
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
